Technical Note | September 11, 2024
Quality analysis across more than 40,000 human biosamples
Get the Resource
Download NowThe use of mass spectrometry for biomarker discovery is crucial to accelerate drug development, enabling identification of dynamic markers of disease and drug response over time. Robust quality metrics across large clinical studies – particularly those involving multiple sites and samples analyzed in independent batches – are essential to advance the application of mass spectrometry for large-scale biomarker discovery.
In this Technical Note, we describe Sapient’s nontargeted mass spectrometry QC workflows and how this comprehensive quality matrix was applied across tens of thousands of human biological samples. This QC analysis demonstrates robust and reproducible data with minimal batch variance, across time, instruments and operators across the large human population-based study.
Learn how Sapient’s extensive quality matrix enables evaluation of sample integrity, sample preparation and handling, automated pipetting, and biomarker extraction, as well as monitoring of chromatographic and mass spectrometry performance at scale and in real time. More than 500 parameters are continuously monitored, with quality metrics that include pooled replicate samples analyzed throughout the study as well as exogenous system performance standards that are introduced, or ‘spiked in’, to each sample.
The Technical Note details a quality analysis of Sapient’s LC-MS workflows applied to assay greater than 40,000 human biosamples in six independent batches as part of a longitudinal human study. Over 35,000 molecular features including metabolites and lipids, were evaluated within the population, making this study among the largest and deepest nontargeted mass spectrometry analyses of humans to date.
